Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: Challenges from a new cause of a rare disease

Oncologist

Volumn 17, Issue 4, 2012, Pages 525-535

  Torino, Francesco ^a   Barnabei, Agnese ^b   de Vecchis, Liana ^a   Salvatori, Roberto ^c   Corsello, Salvatore M ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti CTLA 4 monoclonal antibodies; Hypophysitis; Ipilimumab; Tremelimumab

Indexed keywords

BEVACIZUMAB; CORTICOTROPIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MONOCLONAL ANTIBODY; DACARBAZINE; GLUCOCORTICOID; GLYCOPROTEIN GP 100; GONADOTROPIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GROWTH HORMONE; INTERLEUKIN 2; IPILIMUMAB; LUTEINIZING HORMONE; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; PEPTIDE VACCINE; TEMOZOLOMIDE; THYROTROPIN; TICILIMUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADENOCARCINOMA; ADRENAL INSUFFICIENCY; ARTERITIS; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; ASTHMA; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULITIS; COLITIS; COLON CANCER; CONSTIPATION; DEATH; DERMATITIS; DIARRHEA; DISEASE CLASSIFICATION; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; EDEMA; ENCEPHALITIS; ENTEROCOLITIS; EPISCLERITIS; ERYTHROCYTE APLASIA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GUILLAIN BARRE SYNDROME; HEADACHE; HEPATITIS; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNE SYSTEM; ISCHEMIA; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG ALVEOLITIS; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYASTHENIA GRAVIS; MYOCARDITIS; MYOSITIS; NAUSEA; NEPHRITIS; NEURITIS; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PAIN; PANCREAS ADENOCARCINOMA; PANCREATITIS; PANCYTOPENIA; PERFORATION; PNEUMONIA; POLYARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; REPEATED DRUG DOSE; SARCOIDOSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN EXFOLIATION; SKIN TOXICITY; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; THYROID DISEASE; THYROIDITIS; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UVEITIS; VASCULITIS; VOMITING;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; CTLA-4 ANTIGEN; HUMANS; INFLAMMATION; MELANOMA; PITUITARY DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; SKIN NEOPLASMS;

EID: 84860135451     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0404     Document Type: Article

References (81)

1. Ribas A. Clinical development of the anti- CTLA-4 antibody tremelimumab. Semin Oncol 2010;37:450-454.
2. Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008; 26(15 suppl):LBA90111.
3. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
4. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364: 2517-2526.
5. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-830.
6. Tollefson MK, Karnes RJ, Thompson RH et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer [abstract 168]. Presented at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, CA, March 5-6, 2010.
7. Eggermont AM, Testori A, Maio M et al. Anti- CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol 2010;37:455-459.
8. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic Tlymphocyte antigen-4. J Clin Oncol 2005;23:6043-6053.
9. Chung KY, Gore I, Fong L et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol 2010;28:3485-3490.
10. Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self re- sponses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-8977.
11. Sanderson K, Scotland R, Lee P et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-750.
12. Boasberg P, Hamid O, O'Day S. Ipilimumab: Unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 2010;37:440-449.
13. Kaehler KC, Piel S, Livingstone E et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37:485-498.
14. Wallis N, Bulanhagui CA, Dorazio PC et al. Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer. J Clin Oncol 2008;26(15 suppl):3040.
15. Maker AV, Yang JC, Sherry RM et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29:455-463.
16. Lebbe C, O'Day S, Chiarion-Sileni V et al. Analysis of the onset and resolution of immunerelated adverse events during treatment with ipilimumab in patients with metastatic melanoma [abstract O-015]. Presented at Perspectives in Melanoma XII, Scheveningen, The Hague, The Netherlands, October 2-4, 2008.
17. Wolchok JD, Weber JS, Hamid O et al. Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9-14.
18. Kirkwood JM, Lorigan P, Hersey P et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010;16:1042-1048.
19. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-2289.
20. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13: 6681-6688.
21. Weber JS, O'Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950-5956.
22. Ku GY, Yuan J, Page DB et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-1775.
23. Callahan MK, Wolchok JD, Allison JP. Anti- CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010;37:473-484.
24. Agarwala SS, Ribas A. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 2010;33: 557-569.
25. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I et al. Hypopituitarism Lancet 2007;369: 1461-1470.
26. Caturegli P, Newschaffer C, Olivi A et al. Autoimmune hypophysitis. Endocr Rev 2005;26:599-614.
27. Leporati P, Landek-Salgado MA, Lupi I et al. IgG4-related hypophysitis: A new addition to the hypophysitis spectrum. J Clin Endocrinol Metab 2011; 96:1971-1980.
28. Caturegli P, Lupi I, Landek-Salgado M, et al. Pituitary autoimmunity: 30 years later. Autoimm Rev 2008;7:631-637.
29. Molitch ME, Gillam MP. Lymphocytic hypophysitis. Horm Res 2007;68(suppl 5):145-150.
30. Gutenberg A, Buslei R, Fahlbusch R et al. Immunopathology of primary hypophysitis: Implications for pathogenesis. Am J Surg Pathol 2005;29: 329-338.
31. Bellastella A, Bizzarro A, Coronella C et al. Lymphocytic hypophysitis:Arare or underestimated disease? Eur J Endocrinol 2003;149:363-376.
32. Landek-Salgado MA, Leporati P, Lupi I et al. Growth hormone and proopiomelanocortin are targeted by autoantibodies in a patient with biopsyproven IgG4-related hypophysitis. Pituitary 2011 Aug 23 [Epub ahead of print]. doi: 10.1007/s11102-011-0338-8.
33. Lury KM. Inflammatory and infectious processes involving the pituitary gland. Top Magn Reson Imaging 2005;16:301-306.
34. Rivera JA. Lymphocytic hypophysitis: Disease spectrum and approach to diagnosis and therapy. Pituitary 2006;9:35-45.
35. Thodou E, Asa SL, Kontogeorgos G et al. Clinical case seminar: Lymphocytic hypophysitis: Clinicopathological findings. J Clin Endocrinol Metab 1995;80:2302-2311.
36. Bottazzo GF, Pouplard A, Florin-Christensen A, et al. Autoantibodies to prolactin-secreting cells of human pituitary. Lancet 1975;2:97-101.
37. Castle D, de Villiers JC, Melvill R. Lymphocytic adenohypophysitis. Report of a case with demonstration of spontaneous tumour regression and a review of the literature. Br J Neurosurg 1988;2:401-405.
38. Klein I, Kraus KE, Martines AJ et al. Evidence for cellular mediated immunity in an animal model of autoimmune pituitary disease. Endocr Res Commun 1982;9:145-153.
39. Landek-Salgado MA, Tzou SC, Kimura H et al. Induction of experimental autoimmune hypophysitis in SJL mice. J Vis Exp 2010;17:2182. doi: 10.3791/2182.
40. Lupi I, Zhang J, Gutenberg A et al. From pituitary expansion to empty sella: Disease progression in a mouse model of autoimmune hypophysitis. Endocrinology 2011;152:4190-4198.
41. Imura H, Nakao K, Shimatsu A et al. Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 1993;329: 683-689.
42. Abe T. Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant. Brain Tumor Pathol 2008;25:59-66.
43. Sauter NP, Toni R, McLaughlin CD et al. Isolated adrenocorticotropin deficiency associated with an autoantibody to a corticotroph antigen that is not adrenocorticotropin or other proopiomelanocortinderived peptides. J Clin Endocrinol Metab 1990;70: 1391-1397.
44. Nagai Y, Ieki Y, Ohsawa K et al. Simultaneously found transient hypothyroidism due to Hashimoto's thyroiditis, autoimmune hepatitis and isolated ACTH deficiency after cessation of glucocorticoid administration. Endocr J 1997;44:453-458.
45. Barkan AL, Kelch RP, Marshall JC. Isolated gonadotrope failure in the polyglandular autoimmune syndrome. N Engl J Med 1985;312:1535-1540.
46. Sato N, Sze G, Endo K. Hypophysitis: Endocrinologic and dynamicMRfindings. AJNRAmJ Neuroradiol 1998;19:439-444.
47. Powrie JK, Powell M, Ayers AB et al. Lymphocytic adenohypophysitis: Magnetic resonance imaging features of two new cases and a review of the literature. Clin Endocrinol (Oxf) 1995;42:315-322.
48. Gutenberg A, Larsen J, Lupi I et al. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol 2009;30:1766-1772.
49. Bellastella G, Rotondi M, Pane E et al. Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up. J Clin Endocrinol Metab 2010;95:3750-3757.
50. Dillard T, Yedinak CG, Alumkal J et al. Anti- CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13:29-38.
51. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37: 499-507.
52. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 2005;12:1005-1016.
53. Blansfield JA, Beck KE, TranKet al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28:593-598.
54. Lynch TJ, Bondarenko IN, Luft A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15 suppl): 7531.
55. Di Giacomo AM, Danielli R, Calabrò L et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011;60:467-477.
56. Weber J. Overcoming immunologic tolerance to melanoma: Targeting CTLA-4 with ipilimumab (MDX-010). The Oncologist 2008;13(suppl 4):16-25.
57. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ip- ilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-5598.
58. Yeung SC, Chiu AC, Vassilopoulou-Sellin R et al. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998;19:144-172.
59. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary 2009;12:40-50.
60. Sakane N, Yoshida T, Yoshioka K et al. Reversible hypopituitarism after interferonα therapy. Lancet 1995;345:1305.
61. Concha LB, Carlson HE, Heimann A et al. Interferon- induced hypopituitarism. Am J Med 2003; 114:161-163.
62. Chan WB, Cockram CS. Panhypopituitarism in association with interferon-alpha treatment. Singapore Med J 2004;45:93-94.
63. Tebben PJ, Atkinson JL, Scheithauer BW et al. Granulomatous adenohypophysitis after interferon and ribavirin therapy. Endocr Pract 2007;13:169-175.
64. Ridruejo E, Christensen AF, Mando OG. Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. Eur J Gastroenterol Hepatol 2006;18:693-694.
65. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 2011;103:1572-1587.
66. Klein O, Ebert LM, Nicholaou T et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009; 15:2507-2513.
67. Mirocha S, Elagin RB, Salamat S et al. T regulatory cells distinguish two types of primary hypophysitis. Clin Exp Immunol 2009;155:403-411.
68. Hutfless S, Matos P, Talor MV et al. Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. J Clin Endocrinol Metab 2011;96:E1466-E1471.
69. Ralph C, Elkord E, Burt DJ et al. Modulation of lymphocyte regulation for cancer therapy: A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 2010;16: 1662-1672.
70. Fong L, Kavanagh B, Rini BI et al. A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. J Clin Oncol 2006;24(18 suppl):2508.
71. Small EJ, Tchekmedyian NS, Rini BI et al. A pilot trial of CTLA-4 blockade with human anti- CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13:1810-1815.
72. Weber JS, Targan S, Scotland R et al. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol 2006;24(18 suppl):2510.
73. Gerritsen W, van den Eertwegh AJ, de Gruijl T et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) [abstract 5146]. Presented at the 2008 American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 31 to June 3, 2008.
74. Ansell SM, Hurvitz SA, Koenig PA et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory Bcell non-Hodgkin lymphoma. Clin Cancer Res 2009; 15:6446-6453.
75. Hersh EM, O'Day SJ, Powderly J et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2011;29:489-498.
76. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
77. Hodi FS, Friedlander PA, Atkins MB et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2011;29(15 suppl):8511.
78. O'Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 2010;21:1712-1717.
79. Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27:1075-1081.
80. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-8377.
81. Royal RE, Levy C, Turner K et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010;33:828-833.